1) c lupus erythematosus, and 0.10% Behcet's disease . |
2) reliably predict the risk of breakthrough disease. |
3) h other various types of congenital heart disease. |
4) s host which influence the development of disease. |
5) s of LGI diet on risk factors for chronic disease. |
6) 15 months of follow-up she is free of the disease. |
7) s deadly although potentially preventable disease. |
8) because he may have coexisting pulmonary disease. |
9) and contribute to the development of this disease. |
10) tion and exacerbation of reactive airways disease. |
11) y presenting features, despite widespread disease. |
12) than 40 years to rule out coronary artery disease. |
13) erosclerosis, diabetes, or chronic kidney disease. |
14) nt with AGAAS for initial staging of this disease. |
15) any saw atherosclerosis as a lipid-driven disease. |
16) ry nodules throughout the course of their disease. |
17) stimated, poorly understood, and changing disease. |
18) s a part of the complex of chronic venous disease. |
19) derstanding how to use medicines to treat disease. |
20) Congenital leukemia is a rare disease. |
21) ation often crucial for identification of disease. |
22) ion and its importance in controlling the disease. |
23) in preterm infants with severe pulmonary disease. |
24) travitreal drugs in the treatment of this disease. |
25) second cause of chronic obstructive lung disease. |
26) ultiple sclerosis, and inflammatory bowel disease. |
27) ion, the patient is alive with metastatic disease. |
28) at IL-1 plays a pathological role in this disease. |
29) sicians from appropriately managing their disease. |
30) al dysplasia resembling lysosomal storage disease. |
31) s D exhibited a protective effect in this disease. |
32) rativa (HS) can be a debilitating chronic disease. |
33) utaneous, chronic, recurrent inflammatory disease. |
|